THERAPEUTIC COMPOSITION FOR AUTOIMMUNE CONDITIONS

(19)

(11)

EP 1 610 814 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	02.06.2010 Bulletin 2010/22

(45)	Mention of the grant of the patent:
	24.02.2010 Bulletin 2010/08

(21)	Application number: 04726221.7

(22)	Date of filing: 07.04.2004

(51)

International Patent Classification (IPC):

A61K 38/46^(2006.01)
A61K 38/39^(2006.01)
A61P 37/06^(2006.01)

A61K 31/726^(2006.01)
A61P 19/02^(2006.01)

(86)	International application number:
	PCT/GB2004/001562

(87)	International publication number:
	WO 2004/089405 (21.10.2004 Gazette 2004/43)

(54)	THERAPEUTIC COMPOSITION FOR AUTOIMMUNE CONDITIONS THERAPEUTISCHE ZUBEREITUNG FÜR AUTOIMMUNE ERKRANKUNGEN COMPOSITIONS THERAPEUTIQUES POUR PATHOLOGIES AUTO-IMMUNES

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

(30)

Priority:

07.04.2003 GB 0307989

(43)	Date of publication of application:
	04.01.2006 Bulletin 2006/01

(73)	Proprietor: McEwan Laboratories Ltd
	Pangbourne Berkshire RG8 7JW (GB)

(72)	Inventor:
	MCEWEN, Simon, McEwen Laboratories Limited Pangbourne, Berkshire RG8 7JW (GB)

(74)	Representative: Heaton, Joanne Marie et al
	Stevens, Hewlett & Perkins 1 St. Augustine's Place Bristol BS1 4UD 1 St. Augustine's Place Bristol BS1 4UD (GB)

(56)

References cited: :

EP-A- 1 228 767

CANTANI A ET AL: "Enzyme-potentiated desensitization in children with asthma and mite allergy: A double-blind study" JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, vol. 6, no. 4, 1996, pages 270-276, XP009034038 ISSN: 1018-9068
EGGER J ET AL: "CONTROLLED TRIAL OF HYPOSENSITISATION IN CHILDREN WITH FOOD-INDUCED HYPERKINETIC SYNDROME" LANCET, vol. 339, no. 8802, 1992, pages 1150-1153, XP001156096 ISSN: 0099-5355
MCEWEN L M ET AL: "Enzyme-potentiated hyposensitization. 3. Control by sugars and diols of the immunological effect of beta glucuronidase in mice and patients with hay fever." ANNALS OF ALLERGY. NOV 1973, vol. 31, no. 11, November 1973 (1973-11), pages 543-550, XP009034035 ISSN: 0003-4738
MENGE TIL ET AL: "Monoclonal autoantibodies from patients with autoimmune diseases: Specificity, affinity and crossreactivity of MAbs binding to cytoskeletal and nucleolar epitopes, cartilage antigens and mycobacterial heat-shock protein 60" IMMUNOBIOLOGY, vol. 205, no. 1, March 2002 (2002-03), pages 1-16, XP009034156 ISSN: 0171-2985
WANG DEQUN ET AL: "The influence of HLA-DR4 (0401) on the immune response to type II collagen and the development of collagen induced arthritis in mice" JOURNAL OF AUTOIMMUNITY, vol. 18, no. 2, March 2002 (2002-03), pages 95-103, XP002289829 ISSN: 0896-8411
MATTESON E L: "CURRENT TREATMENT STRATEGIES FOR RHEUMATOID ARTHRITIS" MAYO CLINIC PROCEEDINGS, MAYO MEDICAL VENTURES, ROCHESTER, MN, US, vol. 75, no. 1, January 2000 (2000-01), pages 69-74, XP000944521 ISSN: 0025-6196
VISCHER T L: "Oral desensitization in the treatment of human immune diseases" ZEITSCHRIFT FUER RHEUMATOLOGIE, vol. 54, no. 3, 1995, pages 155-157, XP009034448 ISSN: 0340-1855
TARGONI OLEG S ET AL: "Prevention of murine EAE by oral hydrolytic enzyme treatment" JOURNAL OF AUTOIMMUNITY, LONDON, GB, vol. 12, no. 3, May 1999 (1999-05), pages 191-198, XP002181698 ISSN: 0896-8411

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).